Literature DB >> 23893932

Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk.

Phoebe G Thorpe1, Suzanne M Gilboa, Sonia Hernandez-Diaz, Jennifer Lind, Janet D Cragan, Gerald Briggs, Sandra Kweder, Jan M Friedman, Allen A Mitchell, Margaret A Honein.   

Abstract

PURPOSE: To determine which medications are most commonly used by women in the first trimester of pregnancy and identify the critical gaps in information about fetal risk for those medications.
METHODS: Self-reported first-trimester medication use was assessed among women delivering liveborn infants without birth defects and serving as control mothers in two large case-control studies of major birth defects. The Teratology Information System (TERIS) expert Advisory Board ratings of quality and quantity of data available to assess fetal risk were reviewed to identify information gaps.
RESULTS: Responses from 5381 mothers identified 54 different medication components used in the first trimester by at least 0.5% of pregnant women, including 31 prescription and 23 over-the-counter medications. The most commonly used prescription medication components reported were progestins from oral contraceptives, amoxicillin, progesterone, albuterol, promethazine, and estrogenic compounds. The most commonly used over-the-counter medication components reported were acetaminophen, ibuprofen, docusate, pseudoephedrine, aspirin, and naproxen. Among the 54 most commonly used medications, only two had "Good to Excellent" data available to assess teratogenic risk in humans, based on the TERIS review.
CONCLUSIONS: For most medications commonly used in pregnancy, there are insufficient data available to characterize the fetal risk fully, limiting the opportunity for informed clinical decisions about the best management of acute and chronic disorders during pregnancy. Future research efforts should be directed at these critical knowledge gaps.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  fetal risk; medication; pharmacoepidemiology; pregnancy; teratogen

Mesh:

Substances:

Year:  2013        PMID: 23893932      PMCID: PMC3996804          DOI: 10.1002/pds.3495

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  10 in total

1.  Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.

Authors:  Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz
Journal:  Am J Obstet Gynecol       Date:  2011-04-22       Impact factor: 8.661

2.  Use of over-the-counter medications during pregnancy.

Authors:  Martha M Werler; Allen A Mitchell; Sonia Hernandez-Diaz; Margaret A Honein
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

3.  Report from the CDC. Changes in selected chronic disease-related risks and health conditions for nonpregnant women 18-44 years old BRFSS.

Authors:  Indu B Ahluwalia; Karin A Mack; Ali Mokdad
Journal:  J Womens Health (Larchmt)       Date:  2005-06       Impact factor: 2.681

4.  Trends in outpatient prescription drug use and related costs in the US: 1998-2003.

Authors:  Diane K Wysowski; Laura A Governale; Joslyn Swann
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.

Authors:  Sandra L Kweder
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2008-09

Review 6.  Evolving knowledge of the teratogenicity of medications in human pregnancy.

Authors:  Margaret P Adam; Janine E Polifka; J M Friedman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-07-15       Impact factor: 3.908

7.  ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects.

Authors: 
Journal:  Obstet Gynecol       Date:  2011-06       Impact factor: 7.661

8.  Teratogenicity of recently introduced medications in human pregnancy.

Authors:  W Y Lo; J M Friedman
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

9.  Effect of questionnaire design on recall of drug exposure in pregnancy.

Authors:  A A Mitchell; L B Cottler; S Shapiro
Journal:  Am J Epidemiol       Date:  1986-04       Impact factor: 4.897

10.  Prescription medication borrowing and sharing among women of reproductive age.

Authors:  Emily E Petersen; Sonja A Rasmussen; Katherine Lyon Daniel; Mahsa M Yazdy; Margaret A Honein
Journal:  J Womens Health (Larchmt)       Date:  2008-09       Impact factor: 2.681

  10 in total
  49 in total

1.  The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient.

Authors:  Margaret A Honein; Cynthia A Moore
Journal:  J Allergy Clin Immunol Pract       Date:  2013-10-31

2.  Increasing use of ADHD medications in pregnancy.

Authors:  Carol Louik; Stephen Kerr; Katherine E Kelley; Allen A Mitchell
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-02       Impact factor: 2.890

3.  Acetaminophen in pregnancy and future risk of ADHD in offspring.

Authors:  Jill A Blaser; G Michael Allan
Journal:  Can Fam Physician       Date:  2014-07       Impact factor: 3.275

Review 4.  Frequency and type of medications and vaccines used during pregnancy.

Authors:  Diego F Wyszynski; Kristine E Shields
Journal:  Obstet Med       Date:  2015-09-30

5.  Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants.

Authors:  Elizabeth C Ailes; Regina M Simeone; April L Dawson; Emily E Petersen; Suzanne M Gilboa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-11

6.  Pain medications during pregnancy: data from the Japan environment and children's study.

Authors:  Keiko Yamada; Takashi Kimura; Satoyo Ikehara; Meishan Cui; Yasuhiko Kubota; Kenta Wakaizumi; Takashi Takeda; Hiroyasu Iso
Journal:  J Anesth       Date:  2019-12-16       Impact factor: 2.078

7.  Validation of maternal recall of early pregnancy medication exposure using prospective diary data.

Authors:  Alexandra C Sundermann; Katherine E Hartmann; Sarah H Jones; Eric S Torstenson; Digna R Velez Edwards
Journal:  Ann Epidemiol       Date:  2016-12-09       Impact factor: 3.797

8.  Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies.

Authors:  Molly M Lynch; Linda B Squiers; Katherine M Kosa; Suzanne Dolina; Jennifer Gard Read; Cheryl S Broussard; Meghan T Frey; Kara N Polen; Jennifer N Lind; Suzanne M Gilboa; Janis Biermann
Journal:  Matern Child Health J       Date:  2018-01

9.  Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies.

Authors:  Craig Hansen; Susan E Andrade; Heather Freiman; Sascha Dublin; Katie Haffenreffer; William O Cooper; T Craig Cheetham; Sengwee Toh; De-Kun Li; Marsha A Raebel; Jennifer L Kuntz; Nancy Perrin; A Gabriela Rosales; Shelley Carter; Pamala A Pawloski; Elizabeth M Maloney; David J Graham; Leyla Sahin; Pamela E Scott; John Yap; Robert Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-11-24       Impact factor: 2.890

10.  Medication use and drug-related problems among women at maternity wards-a cross-sectional study from two Norwegian hospitals.

Authors:  J Smedberg; M Bråthen; M S Waka; A F Jacobsen; G Gjerdalen; H Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2016-03-29       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.